Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office December 29, 2022May 23, 2023
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder May 30, 2023May 30, 2023
